Latest Axoltis News & Updates

See the latest news and media coverage for Axoltis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Axoltis

Biotech company developing treatments for neurodegenerative diseases

axoltis.com
Headquarters
Lyon, France
Company type
Private company
Number of employees
15–50

Last updated

Latest news about Axoltis

In short: Axoltis raised €18 million and advanced its lead candidate NX210c into Phase 2 clinical trials for Amyotrophic Lateral Sclerosis.

Company announcements

Axoltis

Axoltis announces NX210c study publication

The study, partnered with InSilicoTrials, shows encouraging results for relapsing-remitting multiple sclerosis. It leverages modeling tools for R&D in neurodegenerative diseases.

Axoltis

Axoltis Pharma raises €18 million for ALS drug candidate

The Series A funding will accelerate phase 2 trials of NX210c for ALS.

Unlock all announcements with a

Media coverage

The Pharma Letter

Axoltis Pharma raises 18 million euros

Axoltis Pharma, a French biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announced the closing of an 18 million euros ($20.9...

Le Journal des Entreprises

Jean-Guillaume Lafay joins the supervisory board of Axoltis Pharma

From left to right: Jean-Guillaume Lafay, member of the supervisory board and Dr Yannick Godfrin, CEO of Axoltis Pharma — Photo: Axoltis Pharma Axoltis...

Unlock all articles with a

Never miss news about Axoltis

Track Axoltis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Axoltis competitors & trending companies

Browse news for competitors to Axoltis and other trending companies.